Superoxide dismutase SodB is a protective antigen against Campylobacter jejuni colonisation in chickens by Chintoan-Uta, Cosmin et al.
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a  b  s  t  r  a  c  t
Campylobacter  is  the  leading  cause  of foodborne  diarrhoeal  illness  in the developed  world  and  consump-
tion  or  handling  of  contaminated  poultry  meat  is the  principal  source  of infection.  Strategies  to control
Campylobacter  in  broilers  prior  to  slaughter  are  urgently  required  and  are  predicted  to limit the  inci-
dence  of  human  campylobacteriosis.  Towards  this  aim,  a puriﬁed  recombinant  subunit  vaccine  based
on the superoxide  dismutase  (SodB)  protein  of C. jejuni M1  was  developed  and  tested  in  White  Leghorn
birds.  Birds  were  vaccinated  on  the  day  of  hatch  and  14 days  later  with  SodB  fused  to glutathione  S-
transferase  (GST)  or puriﬁed  GST  alone.  Birds  were  challenged  with C.  jejuni  M1  at  28 days  of  age  and
caecal  Campylobacter  counts  determined  at weekly  intervals.  Across  three  independent  trials,  the  vaccine
induced  a statistically  signiﬁcant  1 log10 reduction  in caecal  Campylobacter  numbers  in vaccinated  birds
compared  to  age-matched  GST-vaccinated  controls.  Signiﬁcant  induction  of antigen-speciﬁc  serum  IgY
was detected  in  all vaccinated  birds,  however  the  magnitude  and  timing  of  SodB-speciﬁc  IgY did  not  cor-ntibody
rotection
relate with  lower  numbers  of  C.  jejuni.  Antibodies  from  SodB-vaccinated  chickens  detected  the  protein
in  the  periplasm  and  not  membrane  fractions  or  on  the bacterial  surface,  suggesting  that  the  protection
observed  may  not  be  strictly  antibody-mediated.  SodB  may  be useful  as  a constituent  of vaccines  for
control  of  C. jejuni  infection  in  broiler  birds,  however  modest  protection  was  observed  late  relative  to the
life  of  broiler  birds  and  further  studies  are  required  to potentiate  the  magnitude  and  timing  of  protection.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Campylobacter is the leading cause of foodborne diarrhoeal ill-
ess in the developed world. In the United Kingdom in 2013 there
ere 66,575 laboratory-conﬁrmed cases of human campylobacte-
iosis [1], however for every case captured by national surveillance
 further 9.3 are estimated to be undiagnosed in the community and
he true incidence may  therefore exceed 685,000 cases per annum
2]. The European Food Standards Agency estimated that there are
ine million cases of human campylobacteriosis per year across
U27 countries, with the disease and its sequelae (including inﬂam-
atory neuropathies and reactive arthritis) causing 0.35 million
isability-adjusted life years at a cost of D 2.4 billion per annum [3].
∗ Corresponding author. Tel.: +44 0 131 651 9100.
E-mail address: Cosmin.Chintoan-Uta@roslin.ed.ac.uk (C. Chintoan-Uta).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.100
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
Epidemiology unequivocally implicates poultry as the key source of
Campylobacter affecting humans. Over 90% of laboratory-conﬁrmed
human campylobacteriosis is due to C. jejuni and source attribution
studies indicate that up to 80% of such cases may  be due to raw poul-
try meat [3]. The strategic case to control Campylobacter in farmed
poultry is compelling, with a year-long UK-wide survey reporting
contamination of 73% of raw chicken on retail sale [4]. Such levels
are scarcely different from a UK-wide survey in 2007/8 [5]. With a
recent census indicating that c. 900 million broilers are reared each
year in the UK (c. 60 billion worldwide) the scale of the problem is
vast. Though chilling and topical application of chlorinated water,
steam, organic acids or bacteriophages can achieve modest reduc-
tions in surface contamination, control of Campylobacter in broilers
prior to slaughter would substantially reduce cross-contamination
in the abattoir and pathogen entry into the food chain.
Control of Campylobacter may  also improve poultry welfare
and productivity as recent research indicates that C. jejuni elicits
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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rolonged inﬂammatory responses, damage to intestinal mucosa
nd diarrhoea in some commercial broiler lines [6]. Moreover, it
as reported that C. jejuni adversely affects body mass gain in
roilers [7] and Campylobacter-positive birds are also more likely
o exhibit digital dermatitis and signs of colibacillosis [8], though
ausal links have yet to be formally proven.
Previous studies indicate that various classes of recombinant
ampylobacter antigens can elicit protection against colonisation
n chickens, including major ﬂagellar subunits [9,10], membrane
ransport proteins [11,12] and adhesins [13]. However protection
ften required large quantities of antigen or was  observed too late
ost-immunisation to be relevant to modern broiler production,
here birds often enter the food chain at 6–7 weeks of age. One
ossible target for improved vaccines is the superoxide dismutase
rotein SodB. SodB inﬂuences intestinal colonisation of chickens
y C. jejuni [14], and a sodB mutant was reported to be defective
n entry and survival in cultured intestinal cells [15]. Moreover,
 vaccine against Helicobacter pylori based on recombinant SodB
as protective in a murine model [16]. SodB has a high level of
equence conservation amongst sequenced Campylobacters (99%)
nlike some candidate antigens evaluated to date. Based on these
ata, we chose to evaluate a SodB-based subunit vaccine in chick-
ns.
. Materials and methods
.1. Bacterial strains and culture methods
Escherichia coli XL1 (Stratagene, USA) was used for maintenance
f plasmid constructs and E. coli Rosetta BL21 pLysE (Merck Mil-
ipore, UK) was used for protein expression. E. coli strains were
rown in Luria Bertani (LB) broth or agar at 37 ◦C, unless oth-
rwise indicated, with shaking at 200 rpm for liquid cultures. C.
ejuni M1  was used as a source of DNA for gene cloning and
s the challenge strain in vaccination experiments as described
12]. C. jejuni 11168H was used to assess the cross-reactivity
nd subcellular localisation of SodB. C. jejuni strains were grown
n modiﬁed charcoal-cephoperazone-deoxycholate agar (mCCDA)
Oxoid, UK) or in Mueller-Hinton Broth (MH; Oxoid), at 37 ◦C
n a microaerophilic workstation (Don Whitley Scientiﬁc, UK) in
 low oxygen atmosphere (5% O2, 5% CO2 and 90% N2). Liquid
ultures of Campylobacter were grown with shaking at 400 rpm
sing a table top shaker (IKA, Germany) under low oxygen condi-
ions as above. Antibiotics were used at the ﬁnal concentrations
f 100 g/ml ampicillin and 34 g/ml chloramphenicol where
ppropriate.
.2. Constructs for expression of recombinant antigens
The C. jejuni M1  sodB gene was ampliﬁed using primers 5′
GCGCGGGATCCATGTTTGAATTAAGAAAATT 3′ (forward) and 5′
GCGCGGCGGCCGCTTATTTTACAGGGTGAAGTT 3′ (reverse). The
jaA gene was ampliﬁed using the primers: 5′ GGGCTGGCAAGC-
ACGTTTGGTG 3′ (forward) and 5′ CCGGGAGCTGCATGTGTCA-
AGG 3′ (reverse). Both genes were separately cloned as in-frame
-terminal fusions to glutathione S-transferase (GST) in the pGEX-
T1 plasmid (GE Healthcare, UK), through ligation-dependent
loning using the BamHI (5′ end) and NotI (3′ end) restric-
ion sites and transformed into E. coli XL1 Blue. The sodB
nd cjaA genes were re-ampliﬁed using the same forward
rimers described above, but with the reverse primers: 5′GCGCGCGCGGTCGACTTATTTTACAGGGTGAAGTT 3′ for sodB, and
′ CGCGCGCGCGGTCGACTTAGATCTTGCCGCCCTCAATA 3′ for cjaA
nd cloned via the BamHI (3′ end) and the SalI  (5′ end) restriction
ites of the pMal-p2X plasmid (New England Biolabs, UK), to createe 33 (2015) 6206–6211 6207
in-frame fusions with the maltose-binding protein (MBP). The Phu-
sion proof-reading DNA polymerase (Life Sciences, UK) was  used
to generate amplicons for cloning, using the 2-step cycling condi-
tions as recommended by the manufacturer. All plasmid constructs
were veriﬁed by dideoxy chain-termination sequencing (Source
Bioscience, UK), and transformed into electrocompetent E. coli BL21
pLysE Rosetta for protein expression and production.
2.3. Expression, puriﬁcation and validation of recombinant
Campylobacter antigens
Cultures of 500 ml  to 2 l of the E. coli BL21 pLysE Rosetta
cells encoding GST- and MBP-antigen fusions were inoculated
at a 1:100 dilution from a stationary phase overnight cul-
ture and incubated for 3 h, with shaking at 200 rpm, at either
28 ◦C (GST-CjaA and MBP-CjaA) or 37 ◦C (GST, GST–SodB and
MBP–SodB). Cultures were induced with either 0.1 mM  isopropyl
-d-1-thiogalactopyranoside (IPTG; Thermo Scientiﬁc, UK; GST-
CjaA, MBP-CjaA) or 1 mM IPTG (GST, GST–SodB, MBP–SodB) based
on pilot studies to optimise expression and solubility. GST and
MBP  fusion proteins were, respectively, puriﬁed using glutathione
sepharose (GE Healthcare, UK) or amylose resin beads (New
England Biolabs; UK), in batch format, following the manufacturer’s
instructions. Bound GST and MBP  fusion proteins were eluted for 1 h
(GST: 50 mM TrisHCl, 40 mM glutathione, pH 8; MBP: as suggested
by manufacturer), in a volume double that of the beads. Beads were
eluted three times and fusion protein-containing eluates analysed
by sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) using 10% Mini-Protean TGX gels (BioRad, UK)  and
silver staining (Pierce, Life Technologies, UK).
2.4. SDS–PAGE and Western blotting
Protein concentration was  determined using the QuickStart
Bradford Assay (BioRad, UK), following the manufacturer’s pro-
tocol. Recombinant proteins were transferred to polyvinylidene
diﬂuoride (PVDF) membrane using the TransBlot Turbo system
(Biorad, UK) and analysed by Western blot with anti-GST (Santa
Cruz Biotech, USA) or anti-MBP antibody (New England Biolabs,
UK) at 1:10,000 dilutions. Bound antibodies were detected using
appropriate horseradish peroxidase (HRP)-conjugated secondary
antibodies at 1:10,000 dilutions. To assess if the cloned anti-
gens were immunogenic following natural Campylobacter infection,
pooled serum from Campylobacter-infected non-vaccinated White
Leghorn birds collected three weeks post-infection was  used at
a 1:100 dilution. Bound serum IgY was detected with an HRP-
conjugated rabbit-anti chicken IgY (Sigma-Aldrich, UK)  at a 1:3000
dilution. In order to analyse the subcellular localisation of SodB
a Western blot of subcellular fractions (Section 2.9) was probed
with sera from GST–SodB vaccinated birds as above. Blots were
developed using Clarity ECL (BioRad, UK) and autoradiography
(Amersham Hyperﬁlm ECL, GE Lifesciences, UK).
2.5. Vaccination and challenge experiments
All procedures were conducted under Home Ofﬁce project
licence PPL 60/4420, according to the requirements of the Animal
(Scientiﬁc Procedures) Act 1986, with the approval of local eth-
ical review committees. A total of 180 White Leghorn chickens,
obtained on the day of hatch from a Home Ofﬁce licensed breeding
establishment were used. Eggs were incubated and hatched under
speciﬁed-pathogen free conditions. Animals were housed in groups
of up to 20 in colony cages. Groups were of mixed sex and were
wing-tagged for individual identiﬁcation. Water and sterile irradi-
ated feed based on vegetable protein (DBM Ltd., UK) was provided
ad libitum.
6 accin
n
r
c
d
d
l
w
t
t
p
r
v
v
d
G
o
6
d
1
(
a
C
c
A
t
o
l
a
2
o
(
o
a
p
f
m
T
o
f
l
a
2
j
e
s
s
(
t
d
s
t
G
2
o
i
a208 C. Chintoan-Uta et al. / V
Three separate trials were conducted, each including vacci-
ation with GST or GST–CjaA as negative and positive controls
espectively, alongside GST–SodB. Data for the GST and GST–CjaA
ontrol groups was available from an additional experiment that
id not test GST–SodB concomitantly but which had an identical
esign to the three experiments that tested GST–SodB in paral-
el. The experimental design was essentially as described [12], but
ith the following modiﬁcations. White Leghorn chickens rather
han Light Sussex birds were used and GST–CjaA was used rather
han a 6xHis–CjaA fusion [12]. Brieﬂy, twenty birds were used
er experiment per group. A mechanical dispenser and high accu-
acy syringes (Hamilton-Bonaduz, Switzerland) were used for both
accinations and oral gavage. Vaccination was subcutaneous in
olumes of 50 l on each side of the thorax, using 1′′, 21 gauge nee-
les. Antigen preparations were mixed in a 1:1 ratio with TiterMax
old® (Sigma-Aldrich, UK) and each bird received 4.3 × 10−10 mole
f recombinant protein for parity with our earlier studies using
xHis–CjaA [12]. Birds were given the primary vaccination on the
ay of hatch, an identical booster 14 days later and challenged with
07 colony-forming units (CFU) of C. jejuni M1 at 28 days post-hatch
dph) by oral gavage. Starting one week after challenge, between 4
nd 6 birds were removed at weekly intervals to enumerate caecal
ampylobacter by plating 100 l of 10-fold serial dilutions of cae-
al contents in phosphate-buffered saline (PBS) on mCCDA plates.
t the same time, samples of blood and bile were collected for
he measurement of humoral responses. Blood was stored at −4 ◦C
vernight to allow coagulation, after which blood cells were pel-
eted by centrifugation at 3000 × g for 10 min. Serum was collected
nd stored at −80 ◦C until use.
.6. Analysis of humoral immune responses following vaccination
Enzyme-linked immunosorbent assays (ELISAs) were carried
ut to measure antigen-speciﬁc serum IgY and secretory bile IgA
sIgA) against SodB and CjaA. In order to improve the speciﬁcity
f detection of antigen-speciﬁc antibodies, MBP  fusions were used
s the capture antigen in these assays. The assays were done as
reviously described [12], however no blocking step was  used
or the measurement of serum IgY. Coating conditions were opti-
ised using chequerboard analyses for IgY and IgA individually.
o analyse serum IgY, 96 well plates were coated with 0.5 g/ml
f MBP–CjaA or 2 g/ml MBP–SodB. Serum was diluted at 1:500
or GST–CjaA and 1:250 for GST–SodB vaccinated birds. To ana-
yse secretory IgA (sIgA), each recombinant protein was  coated at
 concentration of 1 g/ml and a 1:250 bile dilution was used.
.7. Immunoﬂuorescence microscopy
For assessment of subcellular localisation of SodB within C.
ejuni 11168H cells pooled serum from SodB-vaccinated chick-
ns collected before challenge was used at a 1:500 dilution to
tain Campylobacter cells bound to poly-l-lysine treated glass cover
lips. Where indicated, bacterial cells were permeabilised with 10%
v/v) Triton X-100 for 30 min. A goat anti-chicken IgY conjugated
o AlexaFluor-488 secondary antibody (Abcam, UK) was used for
etection at a 1:500 dilution. Cover slips were mounted on glass
lides using Prolong Gold (Life Technologies). Images were cap-
ured using ﬂuorescent and light microscopy on a Leica DML  (Leica,
ermany) microscope.
.8. Generation of subcellular fractions of C. jejuniFor the preparation of the periplasmic fraction of C. jejuni,  an
smotic shock procedure was used as described [17], with mod-
ﬁcations given in Supplementary Material. The outer membrane
nd inner membrane preparations were made as described [18]e 33 (2015) 6206–6211
with modiﬁcations as given in Supplementary Material. Subcellu-
lar fractions of C. jejuni 11168H were used as preparations of high
purity were already available from other work.
2.9. Statistical analysis
Statistical analyses were performed using Minitab 17 (Minitab,
UK). Individual caecal Campylobacter counts were logarithmically
transformed and the arithmetic mean was  calculated. Signiﬁcant
reductions compared to control groups were determined using
post-hoc Dunnet tests following ﬁtting of a second order hierarchi-
cal general linear model (GLM) that took into account interactions
between time of sample collection and treatment group. The ﬁrst
two outliers in each group, as identiﬁed by the GLM as having
high residuals of over 2.5 log10 CFU/g, were removed from the
data. To test whether humoral immune responses were signiﬁ-
cantly induced relative to control birds the mean OD450 reading
was calculated and a two-tailed Student’s T-test used to detect sig-
niﬁcant increases in antibody levels. Antigen-speciﬁc fold changes
in OD450 of serum IgY in individual birds were calculated by divid-
ing the OD450 measures in each vaccinated bird by the average of
the control group calculated at each sampling time-point. Correla-
tions between serum IgY levels and caecal Campylobacter counts in
individual birds were assessed by ﬁtting of a linear regression to
the data. P values of ≤0.05 were considered signiﬁcant.
3. Results
3.1. Recombinant protein puriﬁcation and validation
The preparations of GST and GST–SodB used in all vaccination
trials and a typical preparation of GST–CjaA (from the ﬁrst vaccina-
tion trial) are shown in Fig. 1A. In Western blots using GST-speciﬁc
antibody the GST–SodB preparation was  detected as a single species
whereas the GST–CjaA preparation appeared to contain a species
of the size of GST only as well as the dominant GST–CjaA fusion
protein (Fig. 1B). A similar pattern was  observed previously when
CjaA was expressed as a fusion to TetC [12]. MBP  fusions were sim-
ilarly validated with an anti-MBP antibody (data not shown). To
determine if the proteins are recognised during C. jejuni infection,
pooled serum from unvaccinated chickens challenged with C. jejuni
M1 was used for Western blots. The serum reacted to GST–CjaA but
not GST–SodB or GST alone (Fig. 1C), implying that of the antigens
tested only CjaA is naturally immunogenic following Campylobac-
ter infection with the M1  strain, at least at the limit of detection of
the method. However, owing to use of denaturing SDS–PAGE only
linear epitopes would be detected.
3.2. Vaccination of chickens with recombinant SodB elicits a
statistically signiﬁcant reduction in caecal Campylobacter
colonisation
We  evaluated the impact of vaccination of chickens with
GST–SodB on protection against homologous challenge with C.
jejuni in three independent trials. In these trials, GST–CjaA was
tested concomitantly as CjaA was  previously demonstrated to be
protective when given as a 6xHis-tagged recombinant protein [12].
GST alone was  given as a negative control. No adverse effects of
vaccination were noted in any of the experimental animals and
no obvious clinical signs were induced by the challenge with C.
jejuni M1  in any of the birds. Caecal Campylobacter loads were
determined at post-mortem examination at weekly intervals fol-
lowing challenge as longitudinal sampling by cloacal swabbing is
less reliable for obtaining viable counts [19]. Across 3 biological
replicates (4–6 birds sampled at each time point per group, per
replicate) the groups vaccinated with GST–SodB had a signiﬁcantly
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3.3. Both SodB- and CjaA-based vaccines induced antigen-speciﬁc
antibody responses following vaccination
In order to measure antigen-speciﬁc humoral responses, serum
IgY and bile IgA responses against C. jejuni M1  antigens in vac-
cinated birds were quantiﬁed by ELISA. Campylobacter antigens
were expressed as MBP  fusions to separate responses to C. jejuni
antigens from the GST fusion partner. A signiﬁcantly higher level
of antigen-speciﬁc serum IgY was induced in the GST–SodB and
GST–CjaA vaccinated groups compared to GST vaccinated groups at
all time-points measured (Fig. 2). However, no signiﬁcant induction
of antigen-speciﬁc bile IgA was  detected in either of the vacci-
nated groups at any of the time points (Fig. 2), similar to previous
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bservations [12]. Further, at the level of individual birds the mag-
itude of antigen-speciﬁc serum IgY responses did not correlate
ith caecal Campylobacter counts for either of the antigens (Fig. 3).
.4. SodB is an intracellular protein in C. jejuni cells
The subcellular localisation of SodB within C. jejuni 11168H cells
as determined by Western blotting of subcellular fractions and
mmunoﬂuorescence microscopy in order to assess the likelihood
f directly neutralising antibodies playing a role in protection fol-
owing vaccination. Sera from GST–SodB vaccinated birds detected
odB only in the periplasmic fraction of C. jejuni 11168H but
ot within the outer or inner membrane fractions (Fig. 4A). The
urity of the fractions was demonstrated by Western blotting with
CapA (an outer membrane auto-transported adhesin, [20]) or
MfrA (a periplasmic fumarate reductase subunit associated with
n inner membrane complex, [21]; Fig. 4A). As a cytoplasmic frac-
ion was not examined we cannot be certain that SodB exists only
n the periplasm of C. jejuni. Immunoﬂuorescence microscopy using
erum from GST–SodB vaccinated birds detected speciﬁc staining
f permeabilised C. jejuni cells, but not non-permeabilised cells
Fig. 4B), supporting a lack of surface exposure of SodB, at least
ithin the limit of detection of the method. Secretion of SodB was
ot assessed in this study. SodB lacks a predicted signal peptide
or secretion in Campylobacter and no evidence of other iron-base
uperoxide dismutases being secreted in bacteria is available in the
iterature.
. DiscussionTowards the aim of developing a vaccine to control Campylobac-
er in its primary reservoir, we evaluated the efﬁcacy of puriﬁed
ST–SodB in reducing Campylobacter colonisation in chickens. The
accine reduced caecal colonisation by approximately 1 log10 at
ig. 4. SodB is absent from the outer membrane and surface of C. jejuni. (A) Immunoblottin
ejuni  11168H with sera from GST–SodB vaccinated birds collected immediately prior to c
rom  the same birds used in panel A and from GST only vaccinated birds as a negative cone 33 (2015) 6206–6211
49 and 56 dph relative to GST-vaccinated birds, however only
the reduction at 56 dph proved to be statistically signiﬁcant. The
GST–CjaA vaccine was  not protective, unlike our previous study
[12], however this could be due to changes in the design of the
experiments. For example the line of birds used was White Leghorn
rather than Light Sussex and the fusion partner and afﬁnity puriﬁca-
tion processes were different. Further, the existence of a truncation
of GST–CjaA (Fig. 1A and B) meant that the molar quantity of
CjaA received by the GST–CjaA vaccinated birds was lower than
when the 6xHis–CjaA fusion was evaluated, and the current study
used the Gold version of TiterMax® as adjuvant which is further
optimised for the promotion of humoral responses. The lack of a
protective effect using GST–CjaA should not cast doubt on the use
of GST fusion vaccines for control of Campylobacter.  Previous stud-
ies have demonstrated protection against colonisation and clinical
symptoms using GST–PorA in a murine model of campylobacterio-
sis [22] and protection against colonisation through the use of a
combined GST and 6xHis-tagged FlpA vaccine in a chicken model
[13].
Though the GST–SodB-based vaccine was  protective, both
immunoﬂuorescence microscopy of whole C. jejuni cells and West-
ern blotting of subcellular fractions indicated the absence of SodB
from the bacterial surface. This is consistent with the subcellular
localisation of SodB within E. coli [23], and indicates that directly
neutralising antibodies binding to the bacteria may  not play a major
role in protection. This is supported by bacteria not being aggluti-
nated when mixed 1:1 (v/v) with serum from GST–SodB vaccinated
birds collected at the time of challenge (data not shown). Further-
more, despite the signiﬁcant induction of humoral responses by the
SodB- and CjaA-based vaccines compared to GST-vaccinated birds,
levels of antigen-speciﬁc serum IgY levels did not correlate with
caecal Campylobacter counts in individual birds (Fig. 3), nor was
the peak of antigen-speciﬁc IgY coincident with the timing of the
protective effect (Fig. 2). In addition, both vaccines failed to induce
antigen-speciﬁc detectable biliary IgA at any of the time intervals
studied. Further characterisation of the nature and consequences of
cell-mediated and humoral responses in protection against Campy-
lobacter colonisation will help to reﬁne vaccine design of vaccines
and inform the selection of adjuvants. Vaccination of transgenic
chickens lacking the Ig heavy chain J segment [24] would allow
the role of antibody in vaccine-mediates protection to be formally
established.
Quantitative risk assessments predict that even a relatively
modest hundred-fold reduction of Campylobacter on broiler car-
casses could reduce the incidence of human disease due to chicken
consumption by 30-fold [25]. Even though protective vaccines
against Campylobacter in chickens have been described, they each
present drawbacks that hinder ﬁeld application. Some are costly to
produce [26], others pose the challenge of attenuated live vectors
that persist at the point of entry into the food chain [11,12], and oth-
ers require very high doses to obtain protection [13]. The GST–SodB
vaccine described herein has the advantages of high sequence con-
servation and high solubility in aqueous medium, making it easy
g of inner membrane, outer membrane and periplasmic subcellular fractions of C.
hallenge. (B) Immunoﬂuorescence microscopy of C. jejuni 11168H stained with sera
trol.
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o produce and deliver under experimental conditions. However, a
uccessful ﬁeld vaccine is likely to require vectoring due to bene-
ts in cost and ease of use. Our study shows proof-of-potential for
nti-Campylobacter vaccination using SodB in chickens and adds
n additional protective antigen to the limited repertoire of those
escribed in the literature to date.
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